Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Taletrectinib

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvation Bio to Present Nonclinical Data at AACR Meeting 2025
    Nuvation Bio to Present Nonclinical Data at AACR Meeting 2025

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325813594/en/Nuvation-Bio-to-Present-New-Nonclinical-Data-for-Taletrectinib-at-the-American-Association-for-Cancer-Research-Annual-Meeting-2025

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    Nuvation To Present Taletrectinib Vs. Crizotinib Data At Lung Congress
    Nuvation To Present Taletrectinib Vs. Crizotinib Data At Lung Congress

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325247942/en/Nuvation-Bio-to-Present-Matching-adjusted-Indirect-Comparison-Data-for-Taletrectinib-vs.-Crizotinib-During-Mini-Oral-Presentation-at-the-European-Lung-Cancer-Congress-2025

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    Nuvation Bio Launches US Expanded Access Program for Taletrectinib
    Nuvation Bio Launches US Expanded Access Program for Taletrectinib

    03 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250203001473/en

    BUSINESSWIRE
    03 Feb 2025
    Share Share
    Nuvation Gets China NMPA Nod For Taletrectinib In ROS1+ NSCLC
    Nuvation Gets China NMPA Nod For Taletrectinib In ROS1+ NSCLC

    06 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250106610712/en

    BUSINESSWIRE
    06 Jan 2025
    Share Share
    Innovent’s Dovbleron Gets Second NDA Approval from NMPA
    Innovent’s Dovbleron Gets Second NDA Approval from NMPA

    02 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-announces-second-new-drug-application-of-dovbleron--taletrectinib-adipate-capsule-ros1-inhibitor-was-approved-by-chinas-national-medical-products-administration-302341276.html

    PR NEWSWIRE
    02 Jan 2025
    Share Share
    FDA Accepts Nuvation’s Taletrectinib for Review in ROS1+ NSCLC
    FDA Accepts Nuvation’s Taletrectinib for Review in ROS1+ NSCLC

    23 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241223905597/en

    BUSINESSWIRE
    23 Dec 2024
    Share Share